Akebia Reports Q1 Net Loss Despite Strong Vafseo Growth and Pipeline Advancement

summarizeSummary

Akebia Therapeutics reported a Q1 2026 net loss of $9.1 million, but highlighted strong commercial growth for Vafseo and significant progress across its clinical pipeline, with sufficient cash to fund operations for at least two years.

check_boxKey Events

• Q1 Financial Results

  The company reported a net loss of $9.1 million for the first quarter of 2026, compared to a net income of $6.1 million in Q1 2025. Total revenues decreased to $53.5 million from $57.3 million year-over-year, primarily due to lower Auryxia sales.

• Strong Vafseo Commercial Growth

  Vafseo net product revenues grew to $15.8 million in Q1 2026, up from $12.0 million in Q1 2025. The number of patients treated with Vafseo increased by 60%, and total prescribers rose by approximately 28% compared to Q4 2025.

• Pipeline Advancement and Data Catalysts

  Akebia provided updates on its kidney disease pipeline, including continued patient enrollment in the praliciguat Phase 2 trial for FSGS. The company expects topline data from the VOCAL Phase 3b trial in Q4 2026 and the VOICE Phase IV trial in early 2027, and plans to initiate a Phase 2 basket study for AKB-097 in H2 2026.

• Cash Position and Runway

  Cash and cash equivalents stood at $162.6 million as of March 31, 2026. The company expects its existing cash resources and cash from operations to be sufficient to fund its current operating plan for at least two years.

auto_awesomeAnalysis

Akebia Therapeutics reported a net loss of $9.1 million for the first quarter of 2026, a reversal from net income in the prior year, primarily driven by lower Auryxia revenues due to generic competition and increased operating expenses. However, the company's key product, Vafseo, demonstrated strong commercial momentum with a 60% increase in patients treated and a 28% rise in prescribers. The filing also provided positive updates on its robust kidney disease pipeline, including progress in multiple clinical trials and upcoming data catalysts, and confirmed a cash runway of at least two years, which is crucial for a life sciences company.